Stock Market News1 week FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus Zacks
FATE Therapeutics’ Q4 loss and revenues improve year over year. Its innovative pipeline is in focus.
XFATE Therapeutics’ Q4 loss and revenues improve year over year. Its innovative pipeline is in focus.
X